Ivermectin: a multifaceted drug of Nobel prize-honoured distinction with indicated efficacy against a new global scourge, COVID-19 (2021)

Peer-Reviewed Study · Santin AD, Scheim DE, McCullough PA, Yagisawa M, Borody TJ · August 2021

Santin AD et al., 2021-08: A pro-ivermectin review arguing that most 2021 meta-analyses found mortality reductions and that Peru's mass distribution coincided with a 74% fall in excess deaths across its ten most-treated states.

Six of seven meta-analyses of IVM treatment RCTs reporting in 2021 found notable reductions in COVID-19 fatalities, with a mean 31% relative risk of mortality vs. controls.

Santin AD et al., 2021-08: A pro-ivermectin review arguing that most 2021 meta-analyses found mortality reductions and that Peru's mass distribution coincided with a 74% fall in excess deaths across its ten most-treated states. Narrative review, no study population of its own; the Peru analysis is ecological (25 states, correlation with distribution intensity, p<0.002 as the authors report). No funding or conflict statement is carried in the PubMed record. Several authors are prominent ivermectin advocates (McCullough, Borody, Scheim) , recorded as attribution, not as an allegation. This is the document that carries the Peru 'natural experiment' claim into the literature and is the counterpart to IVE-29/IVE-30 on the contrary side. Study type: review.